Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Infectious Disease · Hansen's Disease

Finding Your Footing: The Modern Reality of Hansen's Disease

At a Glance

Hansen's disease (leprosy) is a rare but completely curable bacterial infection. With modern multidrug therapy (MDT), patients quickly become non-contagious within days and do not require isolation. Approximately 95% of humans have a natural immunity to the bacteria.

Receiving a diagnosis of Hansen’s disease (traditionally known as leprosy) can feel overwhelming due to the historical weight and stigma of the name. However, the modern reality of the disease is vastly different from ancient myths. Today, Hansen’s disease is a rare, manageable, and completely curable bacterial infection [1][2]. Understanding a few key facts can help ground you as you begin your recovery.

Stabilizing Facts for Your Diagnosis

The most important thing to know is that you are not alone, and your life is not “on hold.”

  • It is curable: Modern multidrug therapy (MDT) is highly effective at killing the bacteria [3][4].
  • You quickly become non-contagious: Once you begin treatment, the bacteria are killed so rapidly that you typically become unable to transmit the disease to others within just a few days of starting medication [5][6].
  • Most people are naturally immune: Approximately 95% of all humans have a natural immune system that is completely capable of fighting off the bacteria that cause Hansen’s disease, even if they are exposed [7][8].
  • It is hard to catch: Transmission generally requires prolonged, close contact (months or years) with someone who has an untreated infection [9][10]. It is not spread through casual contact like shaking hands, sitting next to someone, or sharing a meal.

Understanding the Cause and Transmission

Hansen’s disease is caused by a slow-growing bacterium called Mycobacterium leprae [9]. While it is most common globally in regions with fewer resources, it still occurs in the United States, with about 150 to 200 new cases reported annually [11][12].

In the U.S., cases are increasingly found in the Southeast, particularly Florida [13][14]. In this region, the disease is sometimes linked to contact with nine-banded armadillos, which are natural carriers of the bacteria [15][16]. Handling, hunting, or eating armadillo meat increases the risk of exposure [17][18].

However, some people develop the disease without any known contact with armadillos or other infected people [19][20]. If you do not know how you caught it, please do not panic. Knowing how you caught it does not change how we cure it. Furthermore, Hansen’s disease has a very long incubation period—it can take years for symptoms to appear after exposure, which explains why you might just now be showing symptoms despite no recent exposures [11].

Modern Treatment vs. Historical Stigma

The historical stigma surrounding this disease was born from a time before we understood bacteria or had antibiotics. Historically, people were isolated because there was no cure and the disease could lead to visible physical changes if left untreated.

The modern reality is different:

  1. Early Diagnosis: Because we can now identify the disease early through skin biopsies and physical exams, most patients never develop the physical complications seen in the past [21][22].
  2. No Isolation: There is no need for “leper colonies” or isolation. You can continue to live with your family, go to work, and participate in your community while on treatment.
  3. National Support: In the United States, the National Hansen’s Disease Program (NHDP) provides specialized expertise, medications at no cost to the patient, and guidance for local doctors to ensure every patient receives the best care [23][24].

What to Expect Next

Your treatment will involve a combination of antibiotics taken daily and monthly. The length of treatment typically ranges from 6 to 12 months, depending on the specific type of Hansen’s disease you have [3][25]. While the bacteria are killed quickly, your body may take longer to heal the skin and nerves. Your doctor will monitor you closely for reactions—episodes where the immune system reacts to the dying bacteria—which can be managed with additional medication [26][27].

Focusing on the fact that you are now on a path to a full cure is the most important step in your journey toward health.

Common questions in this guide

Is Hansen's disease (leprosy) curable?
Yes, Hansen's disease is completely curable. It is treated with multidrug therapy (MDT), a specific combination of antibiotics that effectively kills the bacteria causing the infection.
How soon after starting treatment will I no longer be contagious?
You quickly become non-contagious once you start treatment. The medication kills the bacteria so rapidly that you are typically unable to transmit the disease to others within just a few days of taking your first dose.
Do I need to be isolated in a special facility or stay away from my family?
No, modern treatment requires absolutely no isolation. You can continue to live at home with your family, go to work, and participate normally in your community while completing your antibiotic treatment.
How do you catch Hansen's disease?
Transmission generally requires prolonged, close contact over months or years with someone who has an untreated infection. In the Southeastern United States, some cases are also linked to handling, hunting, or eating nine-banded armadillos, which are natural carriers of the bacteria.
Do my family members or close contacts need to be screened?
Because transmission requires prolonged close contact, your doctor may recommend screening your household members as a precaution. However, it is important to know that approximately 95% of people have a natural immunity to the bacteria and will never develop the disease even if exposed.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What type of Hansen's disease do I have, and how does this affect my treatment timeline?
  2. 2.How soon after starting multidrug therapy (MDT) will I no longer be able to pass the bacteria to others?
  3. 3.Given my diagnosis, do my household members or close contacts need to be screened or monitored?
  4. 4.Are you consulting with the National Hansen's Disease Program (NHDP) for my treatment plan?
  5. 5.What symptoms of a 'reaction' should I look out for, and what is the plan if one occurs?
  6. 6.How will we monitor my nerve function during and after treatment to prevent long-term damage?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (27)
  1. 1

    Uncommon Presentation of Lepromatous Leprosy in a Nonendemic Setting: A Case Report.

    Osman ME, Alharby TN, Alhabeeb Y, et al.

    Case reports in medicine 2025; (2025()):8232445 doi:10.1155/carm/8232445.

    PMID: 40979449
  2. 2

    qPCR detection of Mycobacterium leprae DNA in urine samples of leprosy patients using the Rlep gene target.

    Diana D, Harish MC

    Frontiers in molecular biosciences 2024; (11()):1435679 doi:10.3389/fmolb.2024.1435679.

    PMID: 39193223
  3. 3

    Leprosy.

    Grijsen ML, Nguyen TH, Pinheiro RO, et al.

    Nature reviews. Disease primers 2024; (10(1)):90 doi:10.1038/s41572-024-00575-1.

    PMID: 39609422
  4. 4

    United for dignity: four strategic shifts to get to zero leprosy by 2030.

    Warusavithana S, Osman M, Atta H, Hutin YJ

    Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit 2022; (28(2)):93-94 doi:10.26719/2022.28.2.93.

    PMID: 35304905
  5. 5

    Case for diagnosis. Erythematous and infiltrated plaques in the infrahyoid region.

    Bezerra NTC, Schettini APM, Leturiondo AL, Mathias LHMT

    Anais brasileiros de dermatologia 2021; (96(1)):97-99 doi:10.1016/j.abd.2020.03.022.

    PMID: 33288364
  6. 6

    Borderline tuberculoid leprosy mimicking sarcoidosis: A case report.

    Liu J, Wen Y, Xing Y, Wang S

    Medicine 2018; (97(32)):e11616 doi:10.1097/MD.0000000000011616.

    PMID: 30095620
  7. 7

    Editorial Commentary: Evidences of Aerial Route of Mycobacterium leprae Infection and Doubts About Transmission and Natural Protection in Leprosy.

    Frade MA, Foss NT

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2016; (63(11)):1421-1422 doi:10.1093/cid/ciw577.

    PMID: 27558566
  8. 8

    Integrative immune analysis in patients with leprosy reveals host factors associated with mycobacterial control.

    van Hooij A, van Meijgaarden KE, Khatun M, et al.

    EBioMedicine 2025; (118()):105855 doi:10.1016/j.ebiom.2025.105855.

    PMID: 40683203
  9. 9

    Armadillos and leprosy: from infection to biological model.

    Oliveira IVPM, Deps PD, Antunes JMAP

    Revista do Instituto de Medicina Tropical de Sao Paulo 2019; (61()):e44 doi:10.1590/S1678-9946201961044.

    PMID: 31531622
  10. 10

    Leprosy in the Heartland.

    Keegan A, Gubbrud J, Hockhausen K, Peck H

    South Dakota medicine : the journal of the South Dakota State Medical Association 2023; (76(11)):486-493.

    PMID: 38985957
  11. 11

    Pure neuritic leprosy presenting as ulnar nerve neuropathy: a case report of electrodiagnostic, radiographic, and histopathological findings.

    Payne R, Baccon J, Dossett J, et al.

    Journal of neurosurgery 2015; (123(5)):1238-43 doi:10.3171/2014.9.JNS142210.

    PMID: 26047418
  12. 12

    Why we should stop using the word leprosy.

    Deps P, Cruz A

    The Lancet. Infectious diseases 2020; (20(4)):e75-e78 doi:10.1016/S1473-3099(20)30061-X.

    PMID: 32135079
  13. 13

    Case Report of Leprosy in Central Florida, USA, 2022.

    Bhukhan A, Dunn C, Nathoo R

    Emerging infectious diseases 2023; (29(8)):1698-1700 doi:10.3201/eid2908.220367.

    PMID: 37486691
  14. 14

    Leprosy in Florida: a rising concern.

    Cameron S, Cervantes J

    FEMS microbiology letters 2025; (372()) doi:10.1093/femsle/fnaf122.

    PMID: 41190519
  15. 15

    Leprosy in Nonimmigrant Canadian Man without Travel outside North America, 2014.

    Bonnar PE, Cunningham NP, Boggild AK, et al.

    Emerging infectious diseases 2018; (24(1)):165-166 doi:10.3201/eid2401.170547.

    PMID: 29260666
  16. 16

    Leprosy (Hansen's disease): An Update and Review.

    Gilmore A, Roller J, Dyer JA

    Missouri medicine 2023; (120(1)):39-44.

    PMID: 36860602
  17. 17

    Wildlife hunting and the increased risk of leprosy transmission in the tropical Americas: a pathogeographical study.

    Aliaga-Samanez A, Deps PD, Fa JE, et al.

    Infectious diseases of poverty 2025; (14(1)):38 doi:10.1186/s40249-025-01301-z.

    PMID: 40355894
  18. 18

    Human-armadillo interaction in Ceará, Brazil: Potential for transmission of Mycobacterium leprae.

    Kerr L, Kendall C, Sousa CAB, et al.

    Acta tropica 2015; (152()):74-79 doi:10.1016/j.actatropica.2015.07.023.

    PMID: 26232656
  19. 19

    Autochthonous borderline tuberculoid leprosy in a man from Florida.

    Villada G, Zarei M, Romagosa R, et al.

    Leprosy review 2016; (87(1)):101-3.

    PMID: 27255063
  20. 20

    Major risk factors for leprosy in a non-endemic area of the United States: A case series.

    Aslam S, Peraza J, Mekaiel A, et al.

    IDCases 2019; (17()):e00557 doi:10.1016/j.idcr.2019.e00557.

    PMID: 31193361
  21. 21

    Consensus in Brazil on the renaming of leprosy to Hansen's disease.

    Delboni L, Deps P

    Transactions of the Royal Society of Tropical Medicine and Hygiene 2021; (115(9)):1086-1087 doi:10.1093/trstmh/trab115.

    PMID: 34302735
  22. 22

    Small Finger Proximal Interphalangeal Joint Chronic Arthritis Secondary to Leprosy: A Case Report.

    Elbayer AM, Ibrahim MM, Alharami S, et al.

    Cureus 2023; (15(3)):e36915 doi:10.7759/cureus.36915.

    PMID: 37009364
  23. 23

    Hansen's disease patient in Ohio successfully treated with a monthly rifampin, minocycline, and moxifloxacin regimen: a case report.

    Sankovic DE, Hubal AL, Alhajj MA, et al.

    ASM case reports 2025; (1(5)) doi:10.1128/asmcr.00080-24.

    PMID: 41244968
  24. 24

    Novel approaches in the treatment of Hansen's disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States.

    Franco-Paredes C, Garcia-Creighton E, Henao-Martínez A, et al.

    Therapeutic advances in infectious disease 2022; (9()):20499361221135885 doi:10.1177/20499361221135885.

    PMID: 36387060
  25. 25

    Assessment of Clinical, Histopathological, and Bacteriological Findings in Treated Leprosy Patients with Persistent Skin Lesions: A Retrospective Cohort Study.

    Patial M, Hanumanthu V, Chhabra S, et al.

    The American journal of tropical medicine and hygiene 2023; (109(6)):1260-1265 doi:10.4269/ajtmh.23-0084.

    PMID: 37931307
  26. 26

    Reduced vitamin D receptor (VDR) and cathelicidin antimicrobial peptide (CAMP) gene expression contribute to the maintenance of inflammatory immune response in leprosy patients.

    Grossi de Oliveira AL, Chaves AT, Cardoso MS, et al.

    Microbes and infection 2022; (24(6-7)):104981 doi:10.1016/j.micinf.2022.104981.

    PMID: 35462022
  27. 27

    Clinical Pearls: Leprosy Reactions.

    Wu J, Boggild AK

    Journal of cutaneous medicine and surgery 2016; (20(5)):484-5 doi:10.1177/1203475416644832.

    PMID: 27060010

This page provides educational information about the modern reality of Hansen's disease. It is not a substitute for professional medical advice, diagnosis, or treatment from your healthcare provider.

Get notified when new evidence is published on Leprosy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.